CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Sale | −1,148 | $112.25 | $129K | 4,815 |
| 2022-01-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Option exercise · Restricted Stock Unit | −3,500 | 10,500 | ||
| 2022-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,187 | 11,973 | ||
| 2022-01-01 | Lebwohl David EVP, Chief Medical Officer | Sale | −1,051 | $112.24 | $118K | 10,922 |
| 2022-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,187 | 9,563 | ||
| 2022-01-01 | Goddard Glenn EVP, Chief Financial Officer | Option exercise | +3,062 | 3,062 | ||
| 2022-01-01 | Goddard Glenn EVP, Chief Financial Officer | Sale | −1,013 | $112.24 | $114K | 2,049 |
| 2022-01-01 | Goddard Glenn EVP, Chief Financial Officer | Option exercise · Restricted Stock Unit | −3,062 | 9,188 | ||
| 2021-11-05 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +2,400 | $12.62 | $30K | 11,114 |
| 2021-11-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −1,200 | $131.71 | $158K | 9,914 |
| 2021-11-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −452 | $132.62 | $60K | 9,462 |
| 2021-11-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −548 | $134.07 | $73K | 8,914 |
| 2021-11-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −200 | $135.34 | $27K | 8,714 |
| 2021-11-05 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Stock Option (right to buy) | −2,400 | 180,077 | ||
| 2021-10-14 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +2,400 | $12.62 | $30K | 11,114 |
| 2021-10-14 | Lebwohl David EVP, Chief Medical Officer | Sale | −551 | $126.92 | $70K | 10,563 |
| 2021-10-14 | Lebwohl David EVP, Chief Medical Officer | Sale | −849 | $127.81 | $109K | 9,714 |
| 2021-10-14 | Lebwohl David EVP, Chief Medical Officer | Sale | −225 | $129.01 | $29K | 9,489 |
| 2021-10-14 | Lebwohl David EVP, Chief Medical Officer | Sale | −525 | $129.83 | $68K | 8,964 |
| 2021-10-14 | Lebwohl David EVP, Chief Medical Officer | Sale | −250 | $130.47 | $33K | 8,714 |
Page 14 of 40 · 783 trades